UNSPSC 51385804: Meloxicam

This classification denotes a cyclooxygenase inhibitor with the molecular formula C14H13N3O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VG2QF83CGL, chemically known as 4-hydroxy-2-methyl-n-(5-methyl-2-thiazoyl)-2h-1,2-benzothiazine-3-carboxamide-1,1-dioxide but generally known as meloxicam, which bears US NIH Compound Identifier 5281106. European Medicines Agency schedules Meloxicam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08726MIG.

UNSPSC 51385804 Meloxicam is a Commodity code that in practice captures pharmaceutical and medical supply procurement by state and local health agencies, though the most recent solicitation activity does not align with the code's nominal pharmaceutical scope. Seminole County, Florida posted an IFB in June 2026 seeking Naloxone and Safe Drug Deactivation Systems — substances and equipment that fall outside the meloxicam drug classification. State and local health departments, county community health agencies, and special-purpose health districts are the primary issuing bodies under this code, typically sourcing medications and medical supplies through competitive bidding to support public health and emergency response functions.

Seminole County's Naloxone procurement (IFB 60459723LAS, response due July 26, 2023) represents the most recent documented activity. The county sought 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually for quarterly delivery to the Seminole County Community Health Building in Sanford, Florida, with all shipping included in the bid. The contract included a two-year initial term with a one-year renewal option, drug-free workplace and E-Verify compliance requirements, and potential FEMA funding with associated federal environmental compliance obligations. However, the mismatch between the code's pharmaceutical name and the actual goods solicited (opioid antagonists and drug destruction equipment rather than an anti-inflammatory drug) suggests that Meloxicam as a code sees limited relevant recent activity in state and local procurement, or that issuing bodies are tagging broadly under pharmaceutical commodity codes without strict alignment to specific drug classifications.